Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:BHVNNASDAQ:CNTANASDAQ:INDVNASDAQ:MGTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBHVNBiohaven$15.67+1.5%$20.97$14.69▼$55.70$1.60B1.181.24 million shs2.28 million shsCNTACentessa Pharmaceuticals$12.87+2.0%$13.06$7.75▼$19.09$1.72B1.53645,066 shs726,678 shsINDVIndivior$11.26+0.4%$10.27$7.33▼$18.59$1.55B0.981.02 million shs1.30 million shsMGTXMeiraGTx$5.10+0.8%$6.06$3.85▼$8.75$409.86M1.3360,980 shs413,247 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBHVNBiohaven+1.35%-2.50%-26.78%-57.54%-58.76%CNTACentessa Pharmaceuticals+1.98%+2.88%-1.23%-22.61%+47.09%INDVIndivior+0.45%-0.71%+19.34%+33.02%-32.82%MGTXMeiraGTx+0.79%+2.20%-21.42%-30.14%-9.89%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBHVNBiohaven3.4599 of 5 stars4.51.00.00.02.74.20.6CNTACentessa Pharmaceuticals3.5331 of 5 stars4.51.00.00.03.93.30.6INDVIndivior3.2803 of 5 stars3.63.00.00.02.61.71.9MGTXMeiraGTx4.5668 of 5 stars3.53.00.04.82.32.51.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBHVNBiohaven 3.07Buy$59.46279.49% UpsideCNTACentessa Pharmaceuticals 3.00Buy$27.00109.79% UpsideINDVIndivior 3.25Buy$15.0033.21% UpsideMGTXMeiraGTx 3.00Buy$24.00370.59% UpsideCurrent Analyst Ratings BreakdownLatest MGTX, CNTA, INDV, and BHVN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/19/2025BHVNBiohavenRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Sector Perform$54.00 ➝ $21.005/14/2025MGTXMeiraGTxChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$38.00 ➝ $35.005/13/2025BHVNBiohavenCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/13/2025BHVNBiohavenRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$61.00 ➝ $54.005/8/2025CNTACentessa PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform ➝ Outperform$6.005/8/2025CNTACentessa PharmaceuticalsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$30.004/28/2025BHVNBiohavenRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$60.00 ➝ $57.004/24/2025BHVNBiohavenWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy3/31/2025CNTACentessa PharmaceuticalsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$38.003/26/2025CNTACentessa PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.00 ➝ $28.003/20/2025BHVNBiohavenDeutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$60.00(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBHVNBiohavenN/AN/AN/AN/A$5.34 per shareN/ACNTACentessa Pharmaceuticals$15M114.63N/AN/A$2.42 per share5.32INDVIndivior$1.17B1.33$2.28 per share4.94N/A∞MGTXMeiraGTx$34.51M11.88N/AN/A$2.17 per share2.35Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBHVNBiohaven-$408.17M-$9.36N/AN/AN/AN/A-225.12%-158.89%N/ACNTACentessa Pharmaceuticals-$151.09M-$1.81N/AN/AN/AN/A-52.13%-38.01%8/12/2025 (Estimated)INDVIndivior$2M-$0.31N/A6.58N/A-3.96%-241.73%15.09%7/24/2025 (Estimated)MGTXMeiraGTx-$84.03M-$2.32N/A13.420.37-633.05%-146.38%-53.05%8/11/2025 (Estimated)Latest MGTX, CNTA, INDV, and BHVN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025MGTXMeiraGTx-$0.38-$0.51-$0.13-$0.51$4.44 million$1.93 million5/12/2025Q1 2025BHVNBiohaven-$1.67-$2.17-$0.50-$2.17$1.25 millionN/A5/12/2025Q1 2025CNTACentessa Pharmaceuticals-$0.35-$0.20+$0.15-$0.20N/AN/A4/24/2025Q1 2025INDVIndivior$0.22$0.41+$0.19$0.38$240.13 million$266.00 million3/24/2025Q4 2024CNTACentessa Pharmaceuticals-$0.38-$0.34+$0.04-$0.84N/AN/A3/13/2025Q4 2024MGTXMeiraGTx-$0.48-$0.50-$0.02-$0.50$1.50 million$21.39 million3/3/2025Q4 2024BHVNBiohaven-$1.56-$1.85-$0.29-$1.85$100.00 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBHVNBiohavenN/AN/AN/AN/AN/ACNTACentessa PharmaceuticalsN/AN/AN/AN/AN/AINDVIndiviorN/AN/AN/AN/AN/AMGTXMeiraGTxN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBHVNBiohavenN/A2.892.89CNTACentessa Pharmaceuticals0.1521.5221.52INDVIndiviorN/A0.830.65MGTXMeiraGTx0.862.342.34Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBHVNBiohaven88.78%CNTACentessa Pharmaceuticals82.01%INDVIndivior60.33%MGTXMeiraGTx67.48%Insider OwnershipCompanyInsider OwnershipBHVNBiohaven16.00%CNTACentessa Pharmaceuticals7.09%INDVIndiviorN/AMGTXMeiraGTx7.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBHVNBiohaven239102.11 million84.94 millionOptionableCNTACentessa Pharmaceuticals200133.60 million116.56 millionOptionableINDVIndivior1,164137.88 millionN/ANot OptionableMGTXMeiraGTx30080.37 million71.59 millionOptionableMGTX, CNTA, INDV, and BHVN HeadlinesRecent News About These CompaniesFY2025 EPS Estimates for MeiraGTx Cut by Chardan CapitalMay 21 at 2:40 AM | marketbeat.comFY2025 EPS Estimates for MeiraGTx Lowered by Chardan CapitalMay 20, 2025 | americanbankingnews.com12,197,737 Shares in MeiraGTx Holdings plc (NASDAQ:MGTX) Bought by SanofiMay 19, 2025 | marketbeat.comProsight Management LP Sells 509,733 Shares of MeiraGTx Holdings plc (NASDAQ:MGTX)May 17, 2025 | marketbeat.comChardan Capital Lowers MeiraGTx (NASDAQ:MGTX) Price Target to $35.00May 17, 2025 | americanbankingnews.comMeiraGTx (NASDAQ:MGTX) Given New $35.00 Price Target at Chardan CapitalMay 16, 2025 | marketbeat.comMeiraGTx Announces the Presentation of Four Posters at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual MeetingMay 13, 2025 | globenewswire.comMeiraGTx Holdings PLC (MGTX) Reports Q1 Loss, Misses Revenue EstimatesMay 13, 2025 | zacks.comMeiraGTx Reports First Quarter 2025 Financial and Operational ResultsMay 13, 2025 | globenewswire.comFDA grants RMAT status to MeiraGTx’s Parkinson’s treatmentMay 11, 2025 | investing.comMeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the Treatment of Parkinson’s DiseaseMay 9, 2025 | finance.yahoo.comMeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the Treatment of Parkinson's DiseaseMay 9, 2025 | globenewswire.comMeiraGTx (NASDAQ:MGTX) Trading Down 8.7% - Here's What HappenedMay 7, 2025 | marketbeat.comMeiraGTx Holdings plc (NASDAQ:MGTX) Stock Position Decreased by 683 Capital Management LLCMay 4, 2025 | marketbeat.comMeiraGTx (MGTX) to Release Earnings on ThursdayMay 3, 2025 | marketbeat.comCone Rod Dystrophy Market Report 2025-2030, with Profiles of SparingVision, Beacon Therapeutics, Nanoscope Therapeutics, MeiraGTx, Ascidian Therapeutics, jCyte, BlueRock Therapeutics and moreApril 29, 2025 | globenewswire.comMeiraGTx Holdings plc (NASDAQ:MGTX) Shares Bought by Geode Capital Management LLCApril 29, 2025 | marketbeat.comAdage Capital Partners GP L.L.C. Sells 194,521 Shares of MeiraGTx Holdings plc (NASDAQ:MGTX)April 28, 2025 | marketbeat.comLong Focus Capital Management LLC Takes $1.16 Million Position in MeiraGTx Holdings plc (NASDAQ:MGTX)April 25, 2025 | marketbeat.comMeiraGTx Holdings plc (NASDAQ:MGTX) CFO Richard Giroux Sells 24,000 SharesApril 24, 2025 | marketbeat.comMeiraGTx (NASDAQ:MGTX) Stock Price Up 11.9% - Still a Buy?April 24, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMGTX, CNTA, INDV, and BHVN Company DescriptionsBiohaven NYSE:BHVN$15.67 +0.24 (+1.55%) Closing price 05/23/2025 03:59 PM EasternExtended Trading$15.63 -0.04 (-0.25%) As of 05/23/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.Centessa Pharmaceuticals NASDAQ:CNTA$12.87 +0.25 (+1.98%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$12.88 +0.01 (+0.04%) As of 05/23/2025 04:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.Indivior NASDAQ:INDV$11.26 +0.05 (+0.45%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$11.28 +0.02 (+0.13%) As of 05/23/2025 07:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.MeiraGTx NASDAQ:MGTX$5.10 +0.04 (+0.79%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$5.10 0.00 (-0.10%) As of 05/23/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain Advance Auto Parts Jumps on Surprise Earnings Beat Costco Stock at $1K: Dominance or Danger Zone? Williams-Sonoma: A Fundamentally Good Buy On Sale Now Snowflake Breaks Out! Can It Drift Higher in 2025 and Beyond? Alphabet Gets JPMorgan’s Vote of Confidence After Google I/O Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
